Compare KRYS & HXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | HXL |
|---|---|---|
| Founded | 2015 | 1946 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 7.4B |
| IPO Year | 2017 | 1994 |
| Metric | KRYS | HXL |
|---|---|---|
| Price | $340.21 | $96.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $297.60 | $88.30 |
| AVG Volume (30 Days) | 294.7K | ★ 857.8K |
| Earning Date | 05-04-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | $389,130,000.00 | ★ $1,893,900,000.00 |
| Revenue This Year | $38.74 | $10.09 |
| Revenue Next Year | $32.53 | $12.33 |
| P/E Ratio | $187.67 | ★ N/A |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $130.50 | $56.20 |
| 52 Week High | $356.50 | $101.51 |
| Indicator | KRYS | HXL |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 56.21 |
| Support Level | $253.89 | $81.10 |
| Resistance Level | N/A | $97.69 |
| Average True Range (ATR) | 12.77 | 3.22 |
| MACD | 2.68 | 0.53 |
| Stochastic Oscillator | 72.67 | 62.05 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.